Background: In patients with locally-advanced Stage III non-small cell lung cancer, the standard of care used to be concurrent chemotherapy with radiotherapy (chemoRT). The outcomes however remained disappointing with a median progression-free survival of 8 months and only 15% patients surviving at 5 years. Durvalumab is an anti-PD-L1 antibody that bloc…
Keep reading with a 7-day free trial
Subscribe to Hematology Oncology Snippets to keep reading this post and get 7 days of free access to the full post archives.